Thalassemia
Drug research and approvals for thalassemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 63 studies of thalassemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, FDA has 11 approved and 19 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 63
- Trials authorized in Canada: 17
- FDA orphan approvals: 11
- EU medicines: 3
- Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent…NCT07884773 · Phase 3 · Khyber Medical University Peshawar · starts Oct 12, 2026
- Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic ChildrenNCT07725263 · Not reported · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · starts Feb 1, 2026
- Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemiaNCT07680803 · Phase 2 · Fondazione Telethon · starts Jul 6, 2026
- Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta ThalassemiaNCT07673302 · Not applicable · Riphah International University · starts Jun 20, 2026
- Transfusion-Related Changes in Oxidative Stress Biomarkers in NeonatesNCT07672275 · Not reported · Medical University of Graz · starts Dec 12, 2025
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsNCT07599176 · Phase 1 / Phase 2 · National Heart, Lung, and Blood Institute (NHLBI) · starts Jul 8, 2026
- A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)NCT07579949 · Phase 2 · ScinnoHub Pharmaceutical Co., Ltd. · starts Jun 16, 2026
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or…NCT07517133 · Phase 3 · Agios Pharmaceuticals, Inc. · starts Sep 1, 2026
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With…NCT07506863 · Phase 3 · Agios Pharmaceuticals, Inc. · starts Sep 24, 2026
Approved 1
Phase 3 1
- DeferasiroxIron chelating agent
Phase 2 12 of 15
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- Glutamine
- Zinc ion
- BusulfanDNA inhibitor
- Fludarabine
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- PhenytoinSodium channel alpha subunit blocker
- TacrolimusFK506-binding protein 1A inhibitor
- LidocaineSodium channel alpha subunit blocker
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- AmlodipineVoltage-gated L-type calcium channel blocker
Phase 1 or earlier 5
- SirolimusFK506-binding protein 1A inhibitor
- PlerixaforC-X-C chemokine receptor type 4 partial agonist
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- DeferoxamineIron chelating agent
- EtavopivatPyruvate kinase isozymes R/L activator
How its trials ended
446 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 84 whose ending is known, 45% met their primary endpoint, 5% missed it and 50% stopped early.
- Completed, result not reported17539%
- Ongoing12227%
- Status unknown6515%
- Met its primary endpoint389%
- Stopped: other or unclear174%
- Stopped: enrollment or feasibility112%
- Stopped: sponsor or business decision72%
- Stopped: lack of efficacy61%
- Missed its primary endpoint41%
- Stopped: safety1<1%
| Aug 17, 2023 | A rollover study to provide continued access to mitapivat for participants who previously participated in an agios-sponsored mitapivat studyMitapivat (AG-348) | Agios Pharmaceuticals | Ongoing |
| Nov 7, 2022 | An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent alpha- or beta-thalassemia or…Petadeferitrin (SP-420) | Pharmacosmos | Ongoing |
| Apr 6, 2022 | A multicenter study to evaluate the safety, tolerability, and efficacy of a single dose of autologous clustered regularly interspaced short palindromic repeats…EDIT-301 / Mozobil / Filgrastim | Editas Medicine, Inc. | Ongoing |
| Mar 10, 2022 | A phase 2 open-label study to evaluate safety and clinical activity of etavopivat in patients with thalassemia or sickle cell diseaseEtavopivat (FT-4202) | Forma Therapeutics Holdings | Closed |
| Oct 28, 2021 | A phase 3 study to evaluate the safety and efficacy of a single dose of CTX001 in pediatric subjects with transfusion-dependent ¿-thalassemiaExagamglogene autotemcel (CTX001) / Busulfan / Plerixafor | Vertex Pharmaceuticals | Ongoing |
| Sep 8, 2021 | Novel transplant strategy for high-risk thalassemia patients a phase I/II trail of early fludarabine followed by abatacept and sirolimus immunosuppression…Abatacept/ Sirolimus | The Hospital for Sick Children | Ongoing |
| Apr 14, 2021 | A phase 3, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety ofmitapivat in subjects with…Mitapivat (AG-348) | Agios Pharmaceuticals | Ongoing |
| Apr 13, 2021 | A phase 3, double-blind, randomized, placebo conbtrolled, multi-centre study evaluating the efficacy and safety of mitapivat in subjects with…Mitapivat (AG-348) | Agios Pharmaceuticals | Ongoing |
| Nov 13, 2019 | A phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of isis 702843 administered…Isis 702843 (IONIS-TMPRSS6-LRX) | Ionis Pharmaceuticals | Closed |
| Jul 15, 2019 | A phase 1b sequential open label dose ranging study of safety, pharmacokinetics, and preliminary activity of benserazide in subjects with beta thalassemia…Benserazide | Phoenicia Biosciences Inc. | Pending |
| Jul 1, 2026 | CasgevyTreatment of patients aged 2 years and older with transfusion-dependent beta-thalassemia (TDT) | Vertex Pharmaceuticals Inc. | Approved |
| Dec 23, 2025 | AqvesmeTreatment of anemia in adults with alpha- or beta-thalassemia | Agios Pharmaceuticals, Inc. | Approved |
| Jan 16, 2024 | CasgevyTreatment of patients aged 12 years and older with transfusion-dependent beta-thalassemia (TDT) | Vertex Pharmaceuticals Inc. | Approved |
| Aug 17, 2022 | ZyntegloTreatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions | Genetix Biotherapeutics Inc. | Approved |
| Apr 30, 2021 | FerriproxTreatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes; and treatment… | Chiesi USA, Inc. | Approved |
| Apr 30, 2021 | FerriproxTreatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes; and treatment… | Chiesi USA, Inc. | Approved |
| May 19, 2020 | FerriproxFerriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when… | Chiesi USA, Inc. | Approved |
| Nov 8, 2019 | ReblozylREBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC)… | Celgene Corporation | Approved |
| May 18, 2017 | Exjade; Jadenu SprinklesTreatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and… | Novartis Pharmaceuticals Corporation | Approved |
| Jan 23, 2013 | Exjade; Jadenu SprinklesTreatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 14, 2011 | FerriproxTreatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate | Chiesi USA, Inc. | Approved |
| Nov 4, 2025 | DesidustatTreatment of beta-thalassemia | Zydus Lifesciences Limited | Designated |
| Mar 21, 2025 | EtavopivatTreatment of thalassemia | Novo Nordisk Inc. | Designated |
| Jul 11, 2024 | Genetically modified CD34+ hematopoietic stem cells using a…Treatment of beta-thalassemia | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Designated |
| Dec 5, 2023 | Cutamesine dihydrochlorideTreatment of Alpha-thalassemia X-linked disability (ATRX) syndrome | BioPharma Global, a division of Pace Life Sciences | Designated |
| Feb 9, 2024 | CasgevyExagamglogene autotemcel · orphan | Vertex Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Aug 28, 2006 | ExjadeDeferasirox | Novartis Europharm Limited | EMA ↗ |
| Aug 25, 1999 | FerriproxDeferiprone | Chiesi Farmaceutici S.p.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA